Precision Medicine in Pancreatic Cancer: Patient-Derived Organoid Pharmacotyping Is a Predictive Biomarker of Clinical Treatment Response.
Toni T SeppäläJacquelyn W ZimmermanReecha SuriHaley ZlomkeGabriel D IveyAnnamaria SzabolcsChristopher R ShubertJohn L CameronWilliam R BurnsKelly J LafaroJin HeChristopher L WolfgangYing S ZouLei ZhengDavid A TuvesonJames R EshlemannDavid P RyanAlec C KimmelmanTheodore S HongDavid Tsai TingElizabeth D ThompsonRichard Andrew BurkhartPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
PDOs established from tissues obtained from patients previously receiving cytotoxic chemotherapies can be accomplished in a clinically certified laboratory. Sequencing PDOs following biomass expansion improves clinical sequencing quality. High in vitro sensitivity to standard-of-care chemotherapeutics predicts good clinical response to systemic chemotherapy in PDAC. See related commentary by Zhang et al., p. 3176.